Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort

Pharmacotherapy

Volumn 31, Issue 9, 2011, Pages 863-870

  Shin, Jaekyu ^a   Kayser, Steven R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dose prediction; Pharmacogenetic dosing table; Pharmacogenetics; Warfarin

Indexed keywords

AMIODARONE; CARBAMAZEPINE; CYTOCHROME P450 2C9; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENYTOIN; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ACCURACY; ADULT; AFRICAN AMERICAN; AGE; ALLELE; ARTICLE; ASIAN; BODY MASS; CAUCASIAN; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG LABELING; FEMALE; GENDER; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETIC DOSING TABLE; PHARMACOGENETICS; PREDICTION; RACE; RETROSPECTIVE STUDY;

AGED; ANTICOAGULANTS; CONTINENTAL POPULATION GROUPS; DRUG DOSAGE CALCULATIONS; DRUG LABELING; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PHARMACOGENETICS; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; WARFARIN;

EID: 80052201325     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.9.863     Document Type: Article

References (21)

1. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133:S160-98.
2. Bristol-Myers Squibb. Coumadin (warfarin) package insert. Princeton, NJ; 2010.
3. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011;57:612-18.
4. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64.
5. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.
6. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
7. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33.
8. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92.
9. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005; 39:1008-12. (Pubitemid 40695964)
10. Shin J, Cao D. A comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 2011;12:125-34.
11. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010;87:572-8.
12. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541-4. (Pubitemid 38209111)
13. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-41.
14. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African- Americans. Clin Pharmacol Ther 2010;87:459-64.
15. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009;10:261-6.
16. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006;95:782-7.
17. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Human Genet 2007;121:23-34. (Pubitemid 46421137)
18. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-31.
19. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116:2563-70. (Pubitemid 350179221)
20. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005;127:2049-56.
21. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008;9:511-26.